With all the usual caveats of comparing different studies, the KEYNOTE-407 study of Keytruda plus chemo in first-line squamous NSCLC also found that the chances of dying were reduced by around a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback